REG - RTW Biotech Opp. - Update on Corxel Pharmaceuticals

RTW Biotech OpportunitiesAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250624:nRSX0642Oa&default-theme=true

RNS Number : 0642O  RTW Biotech Opportunities Ltd  24 June 2025

LEI: 549300Q7EXQQH6KF7Z84

24 June 2025

RTW Biotech Opportunities Ltd

Update on Corxel Pharmaceuticals

 

RTW Biotech Opportunities Ltd (the "Company"), the London Stock
Exchange-listed investment company focused on identifying transformative
assets with high growth potential across the life sciences sector, notes two
recent announcements from private portfolio company Corxel Pharmaceuticals
("Corxel").

 

Corxel is a clinical-stage biopharmaceutical company dedicated to developing
innovative therapies for patients with cardiometabolic conditions around the
world. Its lead product candidate, CX11, is an investigational oral once-daily
small molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA) for
patients with obesity and overweight. As at 31 May, Corxel was the Company's
second-largest core position, representing 8.3% of NAV.

 

On 17 June, Corxel announced the enrolment of the first patient in its U.S.
Phase 2 trial of CX11, which will evaluate the efficacy and safety of CX11 in
a U.S. population with obesity and overweight. In a previous China Phase 2
trial conducted by its partner, Chengdu Vincentage Pharma Co., Ltd.
("Vincentage"), CX11 demonstrated competitive weight loss with favourable
safety and tolerability in Chinese patients. The U.S. Phase 2 trial aims to
minimise gastrointestinal side effects and will also evaluate a higher dose to
achieve better weight reduction results. Topline data from this trial is
expected to be released in H1 2026.

 

On 21 June, in collaboration with Vincentage, Corxel announced the positive
China Phase 2 clinical results for CX11. In the China Phase 2 trial, weight
reduction was significantly greater at all doses compared to the placebo. A
weight reduction of at least 5% by week 16 occurred in 55% to 90% of the
participants who received CX11, as compared to the 13% who received the
placebo. Treatment with CX11 was associated with improvement in all
weight-related and cardiometabolic metrics that were measured. Of reported
adverse events, most were gastrointestinal and mild to moderate in severity.
No liver toxicity safety signal was identified, nor were any drug-related
serious adverse events reported.

 

Corxel's announcements can be found here
(https://www.corxelbio.com/en/press-releases/corxel-announces-first-patient-enrolled-in-the-us-phase-2-trial-of-cx11-in-obese-and-overweight-patients/)
and here
(https://www.corxelbio.com/en/press-releases/data-from-the-phase-2-clinical-trial-of-cx11vct220-in-china-presented-at-ada-2025/)
.

 

Rod Wong, CIO of RTW Investments, said, "We are encouraged by the promising
results from Corxel's China Phase 2 trial and the launch of its U.S. Phase 2
study, which mark significant milestones in the development of CX11. As a
once-daily oral GLP-1 receptor agonist, CX11 has the potential to offer a more
accessible and patient-friendly alternative to current injectable therapies,
addressing a critical need in the global fight against obesity. The strong
efficacy and favourable safety profile observed so far underscore our
confidence in CX11's potential to become a transformative treatment for
millions of people living with obesity and related cardiometabolic
conditions."

 

Enquiries:

 RTW Investments, LP - Investment Manager               +44 (0)20 7959 6361

 Woody Stileman (Business Development)                  biotechopportunities@rtwfunds.com

 Oliver Kenyon (Business & Corporate Development)

 Krisha McCune (Investor Relations)

 Cadarn Capital - PR & IR Partner

 Lucy Clark (PR)                                        +44 (0)7984 184 461 / lucy@cadarncapital.com

 David Harris (Distribution)                            +44 (0)7368 883 211 / david@cadarncapital.com

 Deutsche Numis - Joint Corporate Broker                +44 (0)20 7260 1000

 Freddie Barnfield

 Nathan Brown

 Euan Brown

 BofA Securities - Joint Corporate Broker               +44 (0)20 7628 1000

 Edward Peel

 Alex Penney

 Altum (Guernsey) Limited                               +44 (0)1481 703 100

 Joanna Duquemin Nicolle

 Sadie Morrison

 

About RTW Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on
identifying transformative assets with high growth potential across the
biopharmaceutical and medical technology sectors. Driven by a long-term
approach to support innovative businesses, RTW Biotech Opportunities Ltd
invests in companies developing next-generation therapies and technologies
that can significantly improve patients' lives. RTW Biotech Opportunities Ltd
is managed by RTW Investments, LP, a leading healthcare-focused
entrepreneurial investment firm with deep scientific expertise and a strong
track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd
(https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/)  for more
information.

 

***********

The information in this announcement may include forward-looking statements,
which are based on the current expectations and projections about future
events, and in certain cases can be identified by the use of terms such as
"may", "will", "should", "expect", "anticipate", "project", "estimate",
"intend", "continue", "target", "believe" (or the negatives thereon) or other
variations thereon or comparable terminology. These forward-looking
statements, as well as those included in any related materials, are subject to
risks, uncertainties and assumptions about the Company and/or its underlying
investments, including, among other things, the development of the applicable
entity's business, trends in its operating industry, expected use of financing
proceeds and future capital expenditures and acquisitions. In light of these
risks, uncertainties and assumptions, the events in the forward-looking
statements may not occur.

The information contained in this announcement is given at the date of its
publication (unless otherwise marked). No reliance may be placed for any
purpose whatsoever on the information or opinions contained in this
announcement or on its completeness, accuracy or fairness.

***********

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDPPUUGQUPAGBW